• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mokhtar Firdauz

    3/19/26 8:11:05 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BTTC alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Mokhtar Firdauz

    (Last)(First)(Middle)
    BLACK TITAN CORP # 8-02 THE BOUSTEADOR,
    10 JALAN PJU 7/6, MUTIARA DAMANSARA,

    (Street)
    SELANGOR DARUL EHSAN

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    Black Titan Corp [ BTTC ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Firdauz Edmin Bin Mokhtar03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $BTTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BTTC
    SEC Filings

    View All

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    3/16/26 9:20:01 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    2/20/26 9:00:16 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    2/19/26 4:15:01 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Flores Garcia Francisco Osvaldo

    3 - Black Titan Corp (0002034400) (Issuer)

    3/19/26 8:14:02 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Mokhtar Firdauz

    3 - Black Titan Corp (0002034400) (Issuer)

    3/19/26 8:11:05 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Chiam Brynner Zet Han

    3 - Black Titan Corp (0002034400) (Issuer)

    3/19/26 8:07:23 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BLACK TITAN CORPORATION APPOINTS CZHANG LIN AS CO-CHIEF EXECUTIVE OFFICER

    NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced the appointment of Czhang Lin as Co-Chief Executive Officer, further strengthening the Company's leadership team as it accelerates its strategic expansion into the digital asset and blockchain sectors. Mr. Lin brings deep expertise in the cryptocurrency and blockchain ecosystem, with a track record of investing in and advising high-growth Web3 projects around the world since 2017. He has collected a vast network over the last 8 years by investing in projects or taking key roles in various funds, that include Binance labs and now currently serves as investment

    11/12/25 8:30:00 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Titan Corporation seeks to explore Long-Term Strategic Crypto Initiatives with potential Strategic Investments in Digital Currencies

    NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation. (NASDAQ:BTTC) (the "Company" or "Black Titan"), today announced plans to seek long-term strategic crypto initiatives with potential strategic investments in digital currencies. Black Titan is exploring the utilization of a digital currency holding strategy to invest in and capitalize on cryptocurrency opportunities. Black Titan is actively exploring additional investments to expand its portfolio through direct coin acquisitions, mining, and fintech-related mergers and acquisitions. Chay W. J., CEO of Black Titan, remarked, "The approach of leveraging debt, equity, and cash flow to build Crypto holdings has delivered stro

    10/6/25 4:15:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

    NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. ("Titan" or "TTNP") today announced the successful closing of its previously announced merger with Black Titan Corporation ("Black Titan") and TalenTec Sdn. Bhd. ("TalenTec"). Following the merger, the combined company's ordinary shares, $0.0001 par value per share, will trade on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC. Pursuant to the Merger and Contribution and Share Exchange Agreement dated August 19, 2024, Titan has become a wholly owned subsidiary of Black Titan Corporation, effective as of October 1, 2025. As part of the transaction, each issued and outstanding share of Titan common stock

    10/3/25 5:26:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    Leadership Updates

    Live Leadership Updates

    View All

    BLACK TITAN CORPORATION APPOINTS CZHANG LIN AS CO-CHIEF EXECUTIVE OFFICER

    NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced the appointment of Czhang Lin as Co-Chief Executive Officer, further strengthening the Company's leadership team as it accelerates its strategic expansion into the digital asset and blockchain sectors. Mr. Lin brings deep expertise in the cryptocurrency and blockchain ecosystem, with a track record of investing in and advising high-growth Web3 projects around the world since 2017. He has collected a vast network over the last 8 years by investing in projects or taking key roles in various funds, that include Binance labs and now currently serves as investment

    11/12/25 8:30:00 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care